Abstract:OBJECTIVES: Cell-free DNA based non-invasive prenatal testing (NIPT) has been shown with closeto-diagnosis sensitivity and specificity in detecting fetal T21, T18, and T13. Future development of this technology focuses on detection of other chromosomal aneuploidies, and more importantly chromosome copy number variants (CNVs) and single-gene mutations. Validation studies were carried out to demonstrate the feasibility of detecting CNVs and single-gene disease by exploiting the cell-free DNA testing strategy and existing NIPT platforms. METHOD: For testing CNVs, 35 plasma samples with known fetal CNVs (>10 Mb in size) were recruited, together with 1077 plasma samples with normal fetal karyotypes as the control. The samples were blindly tested using the routine NIPT testing pipelines adopted at the clinical laboratories of BGI, and analyzed with the proprietary FCAPS protocol. Results were compared to the karyotyping results to calculate the sensitivity and specificity of the NIPT test. For testing single-gene disease, we developed a unique haplotype-assisted approach which was validated in a Maple Syrup Urine Disease (MSUD) case. In a trio family (father, mother in early pregnancy, and proband), targeted sequencing (180X) of the known genes causing MSUD was used to identify the disease causative mutations in the proband child and parents. At 13 gestational weeks, maternal plasma DNA and genomic DNA of the trio family were tested with a customized array at the sequencing depth of 40X and 20X respectively to retrieve the SNPs information for the purpose of parental haplotypes deduction. Linkage analysis and Hidden Markov Model were then used to construct the fetal genotype and haplotype flanking the MSUD mutation region. RESULTS: For CNV detection, with on average 4–5 M reads per sample and the existing NIPT platforms, we were able to use the FCAPS analytic protocol to identify 32 positive samples in total of 35, and generated 6 false positive cases, leading to overall sensitivity and specificity of 91.4% and 99.4% respectively. False positive rate and false negative rate of the test were 0.56% and 0.28% respectively. We also showed that with an increased sequencing depth, the detection power of the test can be further improved. In the MUSD case, deep targeted sequencing in the trio family identified that the proband child carries a missense mutation and a large deletion on BCKDHA gene, which were inherited from the mother and father respectively. With the SNP markers of the proband and parents, parental haplotype of chromosome 19 in 6148 loci were recovered. After fetal haplotype construction, the same alleles as that of the proband in the causative gene BCKDHA were inherited to the fetus, indicating that the fetus is a MSUD patient. This result was later confirmed by invasive diagnosis, and led to a well-informed decision after post-test counselling. CONCLUSIONS: We demonstrate the successful application of NIPT in detection of CNVs larger than 10 Mb without changing much to the current pipelines of aneuploidy detection. It has the potential to be integrated into the current NIPT test and offer extra benefits to the clinical service. The haplotype-assisted approach we developed requires minimum genetic information to accurately predict fetal condition. It has the clinical potential for noninvasive prenatal diagnosis of single gene disease for family with a proband child and seeks a second healthy child.

SSCP analysis by RT-PCR for the prenatal diagnosis of Niemann-Pick disease type C

Noninvasive detection of chromosomal CNV and single gene disease by massively parallel sequencing of cfDNA

CffDNA screening for Niemann–pick disease, type C1: a case series

Genetic and laboratory diagnostic approach in Niemann Pick disease type C

CffDNA screening for Niemann-pick disease, type C1: a case series

[Prenatal Diagnosis of Spinal Muscular Atrophy Using Multiple Ligation-Dependent Probe Amplification].

Increased NPC1 mRNA in skin fibroblasts from Niemann-Pick disease type C patients.

Rapid whole-genome sequencing identifies a novel homozygous NPC1 variant associated with Niemann–Pick type C1 disease in a 7-week-old male with cholestasis

Seven Novel Mutations of the SMPD1 Gene in Four Chinese Patients with Niemann-Pick Disease Type A and Prenatal Diagnosis for Four Fetuses.

Genetic Analysis and Prenatal Diagnosis of a Sporadic Family with Neurofibromatosis Type 1

Importance of the biochemical investigations for the functional characterization of a NPC1 variant identified by exome sequencing

The Application of NIPT Using Combinatorial Probe-Anchor Synthesis to Identify Sex Chromosomal Aneuploidies (scas) in a Cohort of 570 Pregnancies

Prenatal revelation of Niemann-Pick disease type C in siblings

Genetic and Clinical Characterization of Niemann-Pick Disease Type C with Homozygous NPC1 gene mutation: Insights from whole exome sequencing and advanced neuroimaging of two familial cases

Niemann-Pick Disease Type C: Analysis of 7 Patients

Experience of the NPC Brazil Network with a Comprehensive Program for the Screening and Diagnosis of Niemann-Pick Disease Type C

Noninvasive fetal genotyping of single nucleotide variants and linkage analysis for prenatal diagnosis of monogenic disorders

New Cellular Models for Niemann–Pick Type C Disease

Case Report: A Compound Heterozygous Mutations in ASNS Broadens the Spectrum of Asparagine Synthetase Deficiency in the Prenatal Diagnosis

Application of a glycinated bile acid biomarker for diagnosis and assessment of response to treatment in Niemann-pick disease type C1

Clinical, ocular motor, and imaging profile of Niemann-Pick type C heterozygosity